Pharmacokinetic Assessment of ATR-258 Oral Capsule Versus Solution in Type 2 Diabetes: A Randomized, Open-Label, Cross-Over Study

The primary objective of the study is to assess the **pharmacokinetics** of ATR-258 in two different formulations: oral capsule versus oral solution. This evaluation is conducted in healthy volunteers to determine the absorption, distribution, metabolism, and excretion of the drug, which is crucial for understanding its potential therapeutic efficacy and safety profile in managing **Type 2 diabetes (T2D)**. The study's findings will provide essential data to inform dosing strategies and optimize treatment regimens for patients with T2D.

The clinical trial involves participants diagnosed with **Type 2 diabetes (T2D)**. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. The trial does not focus on a vulnerable population, and the selection process for participants has not been specified by the sponsor. Information regarding the total number of participants has not been provided. Additionally, there are no specific lifestyle considerations or key inclusion or exclusion criteria detailed for this study. The sponsor has not disclosed further information regarding the general health status or any other demographic characteristics of the participants.

The clinical trial is designed as an **open-label**, randomized, two-period cross-over study to evaluate the pharmacokinetics of ATR-258 in oral capsule versus oral solution formulations in healthy volunteers. The trial is focused on individuals with **Type 2 diabetes (T2D)** and is categorized as a Phase 3 study. The estimated recruitment start date is April 15, 2024, with an anticipated end date of June 15, 2024, indicating a total trial duration of approximately two months.

Participants will undergo a sequence of study visits, beginning with an inclusion visit, also known as the screening visit, to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive either the oral capsule or oral solution formulation of ATR-258. The study design involves a cross-over, where participants will switch formulations after a specified period, allowing for direct comparison within the same individual. Follow-up visits will be scheduled to monitor pharmacokinetic parameters and ensure participant safety. The end-of-study visit will conclude the trial, where final assessments will be conducted to gather comprehensive data on the pharmacokinetics of both formulations.

The expected length of participant involvement is approximately two months, aligning with the overall trial duration. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial's methodology ensures rigorous data collection and analysis, contributing valuable insights into the pharmacokinetic profile of ATR-258 in different formulations.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it has been designated as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the source data, further details about the **experimental medication** and any **non-experimental treatments** cannot be provided. The trial documentation should be consulted for comprehensive information regarding the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on April 15, 2024, with an estimated completion date of June 15, 2024. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology for measuring, collecting, and analyzing these efficacy parameters, consistent with the standards of Phase 3 clinical trials. The trial will employ validated tools and instruments to ensure the accuracy and reliability of the efficacy assessments. The schedule for these assessments will be aligned with the trial's timeline, ensuring that data collection is systematic and comprehensive. The results will contribute to the understanding of the treatment's efficacy in the specified medical condition, adhering to rigorous clinical and scientific standards.